Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

International Journal of Pharmaceutics

Volumn 447, Issue 1-2, 2013, Pages 38-46

  Serrano, Dolores R ^a   Hernández, Leticia ^b   Fleire, Laura ^a   González Alvarez, Iban ^c   Montoya, Ana ^b   Ballesteros, María P ^a   Dea Ayuela, María A ^a,c   Miró, Guadalupe ^b   Bolás Fernández, Francisco ^a   Torrado, Juan J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

Aggregation state; Albumin microparticles; Amphotericin B; Hemolysis; Passive targeting; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DOG; DRUG FORMULATION; DRUG RELEASE; ELECTRON MICROSCOPY; FEMALE; HEMOLYSIS; LEISHMANIASIS; MALE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVENOUS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; LEISHMANIASIS; MALE; PARTICLE SIZE;

EID: 84874934264     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.02.038     Document Type: Article

References (32)

1. M.L. Adams, D.R. Andes, and G.S. Kwon Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity Biomacromolecules 4 2003 750 757
2. M.L. Adams, and G.S. Kwon Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N- hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length J. Control. Release 87 2003 23 32
3. J.R. Azanza, and J. Barberán Liposomal amphotericin B:a unique pharmacokinetic profile. An unfinished story Rev. Esp. Quimioter 25 2012 17 24
4. I. Bekersky, G.W. Boswell, R. Hiles, R.M. Fielding, D. Buell, and T.J. Walsh Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs Pharm. Res. 16 1999 1694 1701
5. R. Bellmann Clinical pharmacokinetics of systemically administered antimycotics Curr. Clin. Pharmacol. 2 2007 37 58
6. J.E. Bennett, G.J. Hill 2nd, W.T. Butler, and C.W. Emmons Correlation of particle size of intravenous amphotericin B with toxic and chemotherapeutic effects Antimicrob. Agents Chemother. (Bethesda) 161 1963 745 752
7. C.C. Berry, and A.S.G. Curtis Functionalisation of magnetic nanoparticles for applications in biomedicine J. Phys. D: Appl. Phys. 36 2003 198 206
8. T. Blunk, M. Luck, A. Calvor, D.F. Hochstrasser, J.C. Sanchez, B.W. Muller, and R.H. Muller Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting Eur. J. Pharm. Biopharm. 42 1996 262 268
9. J. Brajtburg, and J. Bolard Carrier effects on biological activity of amphotericin B Clin. Microbiol. Rev. 9 1996 512 531
10. P.D. Bryson Pharmacokinetics and toxicokinetics Comprehensive Reviews in Toxicology: for Emergency Clinicians 3rd ed 1996 Taylor & Francis Publishers Washington DC (USA) pp. 61-74
11. M. Cheron, C. Petit, J. Bolard, and F. Gaboriau Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774 J. Antimicrob. Chemother. 52 2003 904 910
12. C.H. Choi, J.E. Zuckerman, P. Webster, and M.E. Davis Targeting kidney mesangium by nanoparticles of defined size Proc. Natl. Acad. Sci. U. S. A. 108 2011 6656 6661
13. S.S. Davis Biomedical applications of nanotechnology-implications for drug targeting and gene therapy Trends Biotechnol. 15 1997 217 224
14. R. Espada, S. Valdespina, M.A. Dea, G. Molero, M.P. Ballesteros, F. Bolas, and J.J. Torrado In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation J. Antimicrob. Chemother. 61 2008 1125 1131
15. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M.P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
16. R. Espada, J.M. Josa, S. Valdespina, M.A. Dea, M.P. Ballesteros, J.M. Alunda, and J.J. Torrado HPLC assay for determination of amphotericin B in biological samples Biomed. Chromatogr. 22 2008 402 407
17. R.M. Fielding, A.W. Singer, L.H. Wang, S. Babbar, and L.S. Guo Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs Antimicrob. Agents Chemother. 36 1992 299 307
18. H. Fukui, T. Koike, A. Saheki, S. Sonoke, Y. Tomii, and J. Seki Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS) Int. J. Pharm. 263 2003 51 60
19. P. Gershkovich, E.K. Wasan, O. Sivak, R. Li, X. Zhu, K.A. Werbovetz, R.R. Tidwell, J.G. Clement, S.J. Thornton, and K.M. Wasan Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice J. Antimicrob. Chemother. 65 2010 535 537
20. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer Biodegradable long-circulating polymeric nanospheres Science 263 1994 1600 1603
21. P.K. Gupta, and C.T. Hung Albumin microspheres. I: Physico-chemical characteristics J. Microencapsul. 6 1989 427 462
22. P.K. Gupta, and C.T. Hung Albumin microspheres. II: Applications in drug delivery J. Microencapsul. 6 1989 463 472
23. S.C. Hartsel, B. Baas, E. Bauer, L.T. Foree Jr.; K. Kindt, H. Preis, A. Scott, E.H. Kwong, M. Ramaswamy, and K.M. Wasan Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha J. Pharm. Sci. 90 2001 124 133
24. A. Knopik-Skrocka, J. Bielawski, M. Glab, A. Klafaczynska, and M. Wulkiewicz A kinetics study of pig erythrocyte hemolysis induced by polyene antibiotics Cell. Mol. Biol. Lett. 8 2003 439 454
25. Mohamed-Ahmed, A.H.; Les, K.A.; Seifert, K.; Croft, S.L.; Brocchini, S.; 2012. Non-covalent complexation of amphotericin-B with poly(α-glutamic acid). Mol. Pharm. (Epub ahead of print).
26. M. Olivier, and C.E. Tanner Susceptibilities of macrophage populations to infection in vitro by Leishmania donovani Infect. Immun. 55 1987 467 471
27. J.S. Salonen Pharmacokinetics of medetomidine Acta Vet. Scand. Suppl. 85 1989 49 54
28. J.A. Sanchez-Brunete, M.A. Dea, S. Rama, F. Bolas, J.M. Alunda, R. Raposo, M.T. Mendez, S. Torrado-Santiago, and J.J. Torrado Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres Antimicrob. Agents Chemother. 48 2004 3246 3252
29. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 2008 2405 2425
30. E.W. van Etten, W. van Vianen, P. Roovers, and P. Frederik Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice Antimicrob. Agents Chemother. 44 2000 1598 1603
31. V. Vanneaux, V. Proust, M. Chéron, M. Besnard, O. Corriol, F. Gimenez, E. Singlas, and P. Legrand A physical and chemical stability study of amphotericin B lipid complexes (Abelcet) after dilution in dextrose 5% The European Journal of Hospital Pharmacy Science 13 2007 10 13
32. T.J. Walsh, V. Yeldandi, M. McEvoy, C. Gonzalez, S. Chanock, A. Freifeld, N.I. Seibel, P.O. Whitcomb, P. Jarosinski, G. Boswell, I. Bekersky, A. Alak, D. Buell, J. Barret, and W. Wilson Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients Antimicrob. Agents Chemother. 42 1998 2391 2398